October 19, 2015 / 10:10 AM / 2 years ago

Valeant Pharma revenue rises 36 pct

Oct 19 (Reuters) - Valeant Pharmaceuticals International Inc , which is under fire for massive price hikes of its two heart drugs, reported a 36 percent rise in quarterly revenue, as sales of dermatology products rose in the United States.

Net income attributable to the Canadian drugmaker fell to $49.5 million, or 14 cents per share, for the third quarter ended Sept. 30, from $275.4 million, or 81 cents per share, a year earlier.

Revenue rose to $2.79 billion from $2.06 billion.

Reporting by Ankur Banerjee in Bengaluru; Editing by Anil D'Silva

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below